EGFR and non-small cell lung carcinoma: NSCLC patients with these activating EGFR mutations are associated with high response rates to EGFR TKIs, including the competitive, ATP-reversible first-generation inhibitors (gefitinib and erlotinib) and the irreversible second- and third-generation inhibitors (afatinib and osimertinib, respectively) [41].